ArticleCureus2025
The Optic Nerve as a New Diagnostic Frontier in Multiple Sclerosis: How the 2024 McDonald Criteria Leverage Multimodal Evaluation for Earlier Diagnosis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The revised 2024 McDonald criteria recognize the optic nerve as a fifth topographical location for dissemination in space (DIS), raising critical questions regarding its diagnostic utility and technical requirements. To analyze this new inclusion, we provide a focused review and illustrate its clinical significance through a case series of three patients where optic nerve assessment was critical for diagnosis. We analyze the operationalization of key diagnostic tools, including optical coherence tomography (OCT) (defining retinal nerve fiber and ganglion cell layer thinning thresholds and inter-eye asymmetry, assessed outside acute neuritis), visual evoked potentials (VEPs) (P100 latency criteria), and 3T orbital magnetic resonance imaging (MRI) (using fat-suppressed T2/short-tau inversion recovery (STIR) and post-gadolinium sequences). Furthermore, we specify how dissemination in time (DIT) was met (presence of CSF-specific oligoclonal bands or new T2/gadolinium-enhancing lesions) and how key mimics (e.g., myelin oligodendrocyte glycoprotein antibody disease (MOGAD), neuromyelitis optica spectrum disorder (NMOSD), ischemic/hereditary neuropathies) were excluded via antibody testing and clinical/laboratory findings. The analysis suggests that the 2024 multiple sclerosis (MS) criteria, by recognizing the optic nerve, may enhance diagnostic sensitivity. In our cohort, multimodal optic nerve assessment was essential to meet DIS criteria, successfully expediting the MS diagnosis and treatment initiation. This multimodal approach also highlights the optic nerve's potential as a source for quantitative biomarkers and a target for future neuroprotective strategies. We conclude that including the optic nerve as a DIS site represents a major diagnostic advance. The presented cases underscore the practical application of the 2024 criteria, stressing the importance of comprehensive evaluation, but also highlighting the critical need for careful exclusion of mimics, vigilance to avoid overdiagnosis, and the necessity of standardized acquisition protocols and robust normative databases for generalizing this approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.